GATA2 and hematologic disorder: The mechanism(s) by which loss-of-function mutations in GATA2 and/or reduced GATA2 levels promote myeloid malignancies remains unclear, but the finding has generated interest in targeting GATA2 for the prognosis or treatment of hematologic disorders.